doi: 10.1111/1756-185X.14801 Epub ahead of print
This single-centre study by Khan, et al. suggests that high-dose methotrexate (25 mg/week, subcutaneously) may be as efficacious as tofacitinib in patients with established RA who are DMARD naïve or have not received a therapeutic dose of DMARDs.
In this this open-label, randomised, controlled, parallel-group, 3-month trial, Khan et al. compared tofacitinib 10 mg and MTX as first-line DMARDs for RA.